NCT05051527 - Study to Evaluate the Effectiveness of Legalon® | Biotech Hunter

Enrollment

362

Participants

Timeline

Start Date

August 8, 2022

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions

Non-alcoholic Fatty Liver Disease (NAFLD)

Interventions

DRUG

Legalon® 140 mg

Legalon® 140 mg as per the Summary of Product Characteristics (SPC) and as per treating Investigator's decision

Trial Locations (1)

Phramongkutklao Hospital, 315 Ratchawithi Rd, Thung Phaya Thai, Ratchathewi, Bangkok